
    
      ALS patients with early impairment of respiratory muscles (FVC around 75%) will be radomised
      to initiate NIV or conventional follow-up.

      The NIV treatment will be initiated during a hospital with the model of ventilator VIVO 40
      (BREAS Medical AD, Sweden) using a pressure support assisted/control mode, with a minimum
      pressure support 10 cm.

      Initial NIV indication in both groups of patients will nocturnal. Patients will be defined as
      tolerant to NIV if they do not refer inconveniences and is able to asleep with NIV.

      The efficacy of the intervention will be compared in both groups with survival until death or
      change to invasive tracheal ventilation as a prymary efficacy parameter.
    
  